Hims & Hers (HIMS) Stock: What Wall Street Expects from Q2 Earnings Today

TLDR

• Hims & Hers reports Q2 earnings after market close today, August 10
• Wall Street expects a loss of $0.05 per share on revenue of ~$698.9 million, up ~28% year-over-year
• Truist says HIMS is “well-positioned” to beat the high end of Q2 revenue guidance, driven by GLP-1 strength
• Options market is pricing in a 14.5% move in either direction following results
• Analyst consensus is Moderate Buy, with an average price target of $30.65, implying ~3% downside from current levels

Hims & Hers Health reports second-quarter 2026 earnings after the market close today, and all eyes are on whether its pivot from compounded to branded GLP-1 drugs is starting to pay off.

Hims & Hers Health, Inc., HIMS

The stock is trading around $31.59, giving the company a market cap of $7.3 billion. It has had a volatile 12 months, swinging from a low of $13.74 to a high of $65.30.

Wall Street is looking for a loss of $0.05 per share on revenue of roughly $698.9 million. That would be a 28% jump year-over-year and a clear step up from Q1, when HIMS posted a $0.40 per share loss on $608 million in sales and missed expectations.

… Continue reading the full article at the original source below.